Among the three inflammatory response subtypes, IR1 patients may derive benefits from anti-CTLA4 therapy, suggesting that the induction of inflammatory signaling could potentially enhance the efficacy of ICB therapy in ccRCC. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.